Panobinostat
Panobinostat (Farydak, pharmaand GmbH) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Multiple myeloma1 | |||
None | + bortezomib and dexamethasone | 3L+ | After at least two prior regimens including bortezomib and an immunomodulatory agent |
Full text of section 4.1 (therapeutic indications)
Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.
Label history
14 changes to the Farydak label since 2017, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes